Agile Therapeutics, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3749 USD | 0.00% | +0.24% | -80.77% |
05-15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
03-28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
1st Jan change | Capi. | |
---|---|---|
-80.77% | 2.57M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.48% | 22.1B | |
-8.54% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt